Nucleome Therapeutics ('Nucleome' or 'the Company'), an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics, is delighted that its ...

The BancAnalysts Association of Boston Conference November 7, 2025 10:35 AM ESTCompany ParticipantsAlexander E.

Q3 2025 Earnings Call Transcript November 5, 2025Charles River Laboratories International, Inc. beats earnings expectations.

The Spinach (R) brand ended Q3 2025 as the second most popular brand in Canada, holding a 4.5% total market share. Spinach (R) flower ranked as the fourth most popular flower brand with 4.9% market ...

Q2 2026 Earnings Call November 5, 2025 8:00 AM ESTCompany ParticipantsSimona King - Chief Financial OfficerMiguel Martin - ...

At Rutgers NJMS, art and music are helping future doctors strengthen empathy, sharpen observation skills and bring humanity ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 ...

Elizabeth McLain wasn’t diagnosed with autism until she was in her 20s, and it only happened then because she had been an ...

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

This study provides a valuable genome-centric characterization of microbial communities across deep sediment cores from a Spartina patens salt marsh. The study provides claims on the metabolic ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025 ...

CLN-049 achieved promising anti-leukemic activity in this heavily pretreated AML population: Anti-leukemic activity was observed at target doses ≥6 μg/kg (n=23, all AML), with a CRc rate of 30%, and ...